NCT05625347View on ClinicalTrials.gov

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 11, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Obstructive Pulmonary FunctionRestrictive Pulmonary Function
Interventions
DRUG

single dose (100 mg) of ASA

powder for oral inhalation via a Dry Powder Inhaler (DPI)

DRUG

single dose (162 mg) of non-enteric-coated chewable aspirin tablets

orally administered

Trial Locations (4)

21209

Sinai Hospital, Baltimore

32789

Clinical Site Partners, LLC CSP Orlando, Winter Park

32808

Omega Research Orlando, LLC, Orlando

08009

Hassman Research Institute, Berlin

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Vectura, Inc.

INDUSTRY